Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 16/20 | 1.00 |
| ▸ | CCNE1 | P24864 | 14/20 | 1.00 |
| ▸ | CDK1 | P06493 | 10/20 | 1.00 |
| ▸ | CDK9 | P50750 | 8/20 | 1.00 |
| ▸ | CCNB1 | P14635 | 8/20 | 1.00 |
| ▸ | CDK5 | Q00535 | 7/20 | 1.00 |
| ▸ | CCNT1 | O60563 | 6/20 | 1.00 |
| ▸ | CCNB2 | O95067 | 6/20 | 1.00 |
| ▸ | CCNB3 | Q8WWL7 | 6/20 | 1.00 |
| ▸ | CDK5R1 | Q15078 | 5/20 | 1.00 |
| ▸ | CACNA1B | Q00975 | 2/20 | 1.00 |
| ▸ | CCNE2 | O96020 | 3/20 | 0.79 |
| ▸ | CCNT2 | O60583 | 1/20 | 0.79 |
| ▸ | CDK7 | P50613 | 5/20 | 0.78 |
| ▸ | CDK4 | P11802 | 3/20 | 0.78 |
| ▸ | CCND1 | P24385 | 3/20 | 0.78 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.78 |
| ▸ | CCNH | P51946 | 3/20 | 0.78 |
| ▸ | CCNK | O75909 | 3/20 | 0.78 |
| ▸ | CDK12 | Q9NYV4 | 3/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Olomoucine Ii SCHEMBL31069520 | 1.00 | CDK2 (1.00) | CDK2CCNE1CDK1CDK9CCNB1 | |
| Olomoucine Ii SCHEMBL3514137 | 1.00 | CDK2 (1.00) | CDK2CCNE1CDK1CDK9CCNB1 | |
| SCHEMBL1352423 | 0.90 | CDK2 (0.81) | CDK2CCNE1CDK1CDK9CCNB1 | |
| SCHEMBL15117753 | 0.88 | CDK2 (0.80) | CDK2CCNE1CDK1CDK9CCNB1 | |
| SCHEMBL1441193 | 0.88 | CDK2 (0.85) | CDK2CCNE1CDK1CDK9CCNB1 | |
| SCHEMBL15118130 | 0.88 | CDK2 (1.00) | CDK2CCNE1CDK1CDK9CCNB1 | |
| (Rs)-Roscovitine SCHEMBL172593 | 0.87 | CDK1 (1.00) | CDK2CCNE1CDK1CDK9CCNB1 | |
| (S)-Roscovitine SCHEMBL2907488 | 0.87 | CDK1 (1.00) | CDK2CCNE1CDK1CDK9CCNB1 | |
| Seliciclib SCHEMBL94728 | 0.87 | CDK1 (1.00) | CDK2CCNE1CDK1CDK9CCNB1 | |
| (Rs)-Roscovitine SCHEMBL15163619 | 0.87 | CDK1 (1.00) | CDK2CCNE1CDK1CDK9CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 170 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118403163-A | Medical application and pharmaceutical composition of PIN1/CDK1-pVHL signal path interfering agent | 暨南大学 | 2024-07-30 | — | — | CN | claimed |
| US-20240009205-A1 | THERAPEUTIC COMBINATION FOR THE TREATMENT OF BREAST CANCER | IFOM -FONDAZIONE ISTITUTO FIRC DI ONCOLOGIA MOLECOLARE (37%) (IT) | 2024-01-11 | — | — | US | claimed |
| EP-4157246-A1 | THERAPEUTIC COMBINATION FOR THE TREATMENT OF BREAST CANCER | Fondazione Istituto Firc Di Oncologia Molecolare (IFOM) (IT) | 2023-04-05 | — | — | EP | claimed |
| US-20230080670-A1 | METHODS AND COMPOSITIONS FOR TREATING TUMORS USING TRANSCRIPTION INHIBITION AND DNA DAMAGE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-03-16 | — | — | US | claimed |
| CN-115400213-A | Medical application and pharmaceutical composition of CDK1-USP29-Twist1 signal channel down-regulator | 暨南大学 | 2022-11-29 | — | — | CN | claimed |
| US-11452716-B2 | Pharmaceutical composition and use thereof | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2022-09-27 | — | — | US | claimed |
| WO-2021214119-A1 | THERAPEUTIC COMBINATION FOR THE TREATMENT OF BREAST CANCER | IFOM - FONDAZIONE ISTITUTO FIRC DI ONCOLOGIA MOLECOLARE (IT) | 2021-10-28 | — | — | WO | claimed |
| US-20210275522-A1 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | ASCENTAGE PHARMA SUZHOU CO LTD (CN) | 2021-09-09 | — | — | US | claimed |
| US-10987356-B2 | Dual inhibition of CDK and HSP90 destabilize H1F1 α and synergistically induces cancer cell death | INSTITUTE FOR CANCER RESEARCH (US) | 2021-04-27 | — | — | US | claimed |
| US-20200297704-A1 | NOVEL PHARMACEUTICAL COMPOSITION AND USE THEREOF | ASCENTAGE PHARMA GROUP CORP LIMITED (CN) | 2020-09-24 | — | — | US | claimed |
| EP-3706741-A1 | PHARMACEUTICAL COMPOSITION AND USE THEREOF | Ascentage Pharma (Suzhou) Co., Ltd. (CN) | 2020-09-16 | — | — | EP | claimed |
| EP-3697411-A1 | NOVEL PHARMACEUTICAL COMPOSITION AND USE THEREOF | Ascentage Pharma Group Corp Limited (CN) | 2020-08-26 | — | — | EP | claimed |
| US-10729692-B2 | Dual inhibition of CDK and HSP90 destabilize HIF1alpha and synergistically induces cancer cell death | INSTITUTE FOR CANCER RESEARCH (US) | 2020-08-04 | — | — | US | claimed |
| CN-111214471-A | Pharmaceutical composition and use thereof | 苏州亚盛药业有限公司 | 2020-06-02 | — | — | CN | claimed |
| US-20200155554-A1 | Dual Inhibition Of CDK And HSP90 Destabilize H1F1alpha And Synergistically Induces Cancer Cell Death | INSTITUTE FOR CANCER RESEARCH D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER | 2020-05-21 | — | — | US | claimed |
| US-20180243306-A1 | Dual Inhibition Of CDK And HSP90 Destabilize HIF1alpha And Synergistically Induces Cancer Cell Death | INSTITUTE FOR CANCER RESEARCH D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER | 2018-08-30 | — | — | US | claimed |
| WO-2013071415-A1 | TARGETING THE RB PATHWAY FOR THE PREVENTION OF CANCER | UNIVERSITY HEALTH NETWORK (CA) | 2013-05-23 | — | — | WO | claimed |
| US-20260053799-A1 | COMPOUNDS FOR TREATING CANCER | EVEXTA BIO (FR) | 2026-02-26 | — | — | US | disclosed |
| WO-2008021210-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | COMBINATORX, INCORPORATED (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | CHDI, INCORPORATED | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260053799-A1 | COMPOUNDS FOR TREATING CANCER | NCOA1, AR, ESR2 | CDK2 1129/4885CCNE1 1063/4885CDK1 949/4885 |
| US-20210275522-A1 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | CDK2, CDK5, CDK6 | CDK2 1/4885CCNE1 89/4885CDK1 10/4885 |
| US-20200297704-A1 | NOVEL PHARMACEUTICAL COMPOSITION AND USE THEREOF | TP53, CDK2, RB1 | CDK2 2/4885CCNE1 53/4885CDK1 8/4885 |
| US-11452716-B2 | Pharmaceutical composition and use thereof | TP53, RB1, CDK20 | CDK2 4/4885CCNE1 55/4885CDK1 12/4885 |
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | HTT, SNCA, NLN | CDK2 3817/4885CCNE1 4860/4885CDK1 3289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.